n-dodecyl-B-D-maltoside + Cretostimogene Grenadenorepvec for carcinoma, transitional cell

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 1 Nov 2023: Trial registered, NCT06111235
  2. 14 Dec 2023: Trial started, NCT06111235

The trials

NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

State
Under way
Phase
Phase 3
People
367 taking part
Started
14 Dec 2023
Primary completion
Nov 2026
Arms
Cretostimogene after TURBT
Results
None posted
  1. 1 Nov 2023: Trial registered
  2. 14 Dec 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.